dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Su, Wu-Chou |
dc.contributor.author | Schuler, Martin |
dc.contributor.author | Nam, Do-Hyun |
dc.contributor.author | Lim, Darren Wan-Teck |
dc.contributor.author | Azaro Pedrazzoli, Analía Beatriz |
dc.contributor.author | Bauer, Todd |
dc.contributor.author | Bang, Yung-Jue |
dc.date.accessioned | 2021-11-05T06:58:36Z |
dc.date.available | 2021-11-05T06:58:36Z |
dc.date.issued | 2020-02 |
dc.identifier.citation | Bang YJ, Su WC, Schuler M, Nam DH, Lim WT, Bauer TM, et al. Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts. Cancer Sci. 2020 Feb;111(2):536–547. |
dc.identifier.issn | 1349-7006 |
dc.identifier.uri | https://hdl.handle.net/11351/6502 |
dc.description | Amplificació del MET; Capmatinib; Tumors sòlids |
dc.description.sponsorship | Novartis Pharmaceuticals Corporation |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | Cancer Science;111(2) |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Proteïnes quinases - Inhibidors - Ús terapèutic |
dc.subject | Càncer - Tractament |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Proto-Oncogene Proteins c-met |
dc.subject.mesh | /antagonists & inhibitors |
dc.title | Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1111/cas.14254 |
dc.subject.decs | neoplasias |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | proteínas protooncogénicas c-met |
dc.subject.decs | /antagonistas & inhibidores |
dc.relation.publishversion | https://doi.org/10.1111/cas.14254 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Bang YJ] Seoul National University College of Medicine, Seoul, Korea. [Su WC] National Cheng Kung University Hospital, Tainan, Taiwan. [Schuler M] Department of Medical Oncology, West German Cancer Center, University DuisburgEssen and German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany. [Nam DH] Samsung Medical Center, Seoul, Korea. [Lim WT] National Cancer Centre, Singapore. [Bauer TM] Sarah Cannon Research Institute/ Tennessee Oncology, PLLC, Nashville, Tennessee, USA. [Azaro A] Servei d’Oncologia Mèdica, Unitat d’Investigació de Teràpia Molecular, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Farmacologia, Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 31778267 |
dc.identifier.wos | 000504804900001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |